Skip to content
search
People Danny Yeung's Prenetics And Adrian Cheng's Artisan Acquisition Plan US$1.3 Billion Merger

Danny Yeung's Prenetics And Adrian Cheng's Artisan Acquisition Plan US$1.3 Billion Merger

Danny Yeung's Prenetics And Adrian Cheng's Artisan Acquisition Plan US$1.3 Billion Merger
By Jianne Soriano
By Jianne Soriano
July 16, 2021
Prenetics—the Hong Kong biotech company behind rapid Covid-19 tests—is about to become the first billion-dollar Hong Kong start-up to go public

Two prominent Hong Kong entrepreneurs and members of the Tatler community are joining forces. 

Danny Yeung—a Tatler cover star, Gen.T 2019 honouree and Impact List honouree—is planning to take his biotech company, Prenetics, public on the Nasdaq stock exchange through a merger with Artisan Acquisition, a special purpose acquisitions company (SPAC) led by Adrian Cheng, the CEO and executive vice chairman of Hong Kong-listed New World Development, who has starred on multiple Tatler covers and has been featured on both Tatler's Impact List and Culture List.

The deal is reported to be worth US$1.3 billion and is expected to be completed by the end of the year. Artisan has already raised US$339 million and has agreed on another US$60 million with investment firm Aspex and PAG, according to CNBC. Companies such as UBS, Citi, Credit Suisse and CICC are reported to be serving as financial advisers on the deal.

Prenetics—which develops rapid Covid-19 tests and researches genetic sequencing—is expected to earn more than US$200 million in revenue this year, with annual revenue expected to reach US$600 million by 2025. 

See also: Prenetics Founder Danny Yeung On Helping Restore Normality During Covid-19

Prenetics made a splash when it brought the University of Oxford's rapid Covid-19 test to the masses—most famously providing them to professional football teams in the UK, who could only resume playing during the pandemic because they had access to Prenetics tests. “Who would think a Hong Kong company would be helping the Premier League resume their season?” Yeung told Tatler last year. “That drives me every day: knowing we’re at the forefront, not just in Hong Kong, but in the world for Covid-19. We are very proud that this started from Hong Kong.”

Prenetics is also behind CircleDNA, which sells at-home test kits that detect disease risk, food sensitivities, personality and behavioural traits, and has been at the forefront of mass Covid-19 testing in Hong Kong.

Meanwhile, Cheng's Cayman Islands-based Artisan Acquisition went public in March 2020, raising US$300 million in the US alone. It is now traded on the Nasdaq. The company targets global healthcare, technology and consumer companies.

Cheng's New World Development is reported to have US$88 billion in assets. In Hong Kong, its most visible recent investment has been a US$2.6 billion redevelopment of Victoria Dockside on the Tsim Sha Tsui harbourfront. The area is now home to a 65-storey tower that houses both the Rosewood Hong Kong hotel and K11 Atelier offices; the 21-storey K11 Artus, featuring luxury residences; and K11 Musea, an art, culture and retail complex. 

“K11 Musea is more than a shopping centre," Cheng told Tatler just before it opened to the public. "I see it as a Silicon Valley of culture, and a gift to Hong Kong’s next generation. It’s a place where people can find something new, something that inspires them—and I hope it will continue to do so for a long time."

See also: The Future Of Retail Is Now: Adrian Cheng And His Team Of 100 Creatives Debut K11 Musea

Tags

People adrian cheng danny yeung prenetics new world development artisan acquisition

clear
keyboard_arrow_up

In order to provide you with the best possible experience, this website uses cookies. For more information, please refer to our Privacy Policy.

close